Biotechnology News and Research

RSS

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.

19 Jul 2010

GABA disrupts working memory in neurofibromatosis type 1 patients

Imagine if your brain lost its working memory - the ability to hold and manipulate information in your mind's eye. That's the plight faced by millions of people with neurofibromatosis type 1, or NF1. The genetic condition affects one in 3,500 people and is the most common cause of learning disabilities.Now a UCLA research team has uncovered new clues about how NF1 disrupts working memory. Published in the July 12 online edition of Proceedings of the National Academy of Sciences, the findings suggest a potential drug target for correcting NF1-related learning disabilities.

17 Jul 2010

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.

17 Jul 2010

Maxygen's option and licensing arrangement with Cangene expires

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation has expired. Under the agreement, Maxygen had granted Cangene an option to obtain an exclusive license to Maxygen's proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome.

17 Jul 2010

ICON opens purpose-built clinical pharmacology unit within CMFT campus

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the official opening of a purpose-built clinical pharmacology unit within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester, UK. Initial studies in the unit utilising translational medicine methodologies to expedite drug development projects began in June, and already 110 volunteers have participated in studies there.

17 Jul 2010

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

Amgen granted FDA priority review designation for denosumab BLA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

17 Jul 2010

Simulations Plus third-quarter consolidated revenues increase 14.9% to record $3.1 million

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its third quarter of fiscal year 2010 ended May 31, 2010 (3QFY10).

17 Jul 2010

Lab-on-Bead technology helps researchers cut years from drug development

New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.

16 Jul 2010

Bioethics through the lens of literature

What if I were grown only so that my organs could be harvested, and I had to care for others whose organs are being taken, too, while I wait for my own death? What if doctors cut off a piece of the tumor that killed me and grew it in a lab for the next sixty years? What if scientists discovered a gene that would ensure my happiness no matter what life throws at me?

16 Jul 2010

Study analyzes global oncology community's Twitter utilization to enhance discussion at ASCO 2010

JuvoLab, a company focused on value creation in the life sciences industry, today announced the release of a unique study detailing the entire global oncology community's utilization of Twitter to enhance scientific discussion at the ASCO 2010 Annual Meeting. This pioneering study analyzed over 4450 tweets, generated by more than 680 users over the course of the conference, and provides clarity and insight into the use of Twitter from breaking clinical news and engaging in clinical discussion to compliant corporate promotion by industry leaders.

16 Jul 2010

Restricted diet can extend lifespan: Study

New research being presented this week is giving scientists new insight into why a restricted diet can lead to a longer lifespan and reduced incidence of age-related diseases for a wide variety of animals. Scientists have known for some time that a restricted diet can extend the lifespan of certain animals but this work shows how it affects ageing mechanisms - and significantly has also shown that the effects occur even if the restricted diet is adopted later in life.

16 Jul 2010

WPI researchers measure molecular forces that enable cranberry juice to fight off urinary tract infections

Revealing the science behind the homespun advice, a team of researchers at Worcester Polytechnic Institute (WPI) has identified and measured the molecular forces that enable cranberry juice to fight off urinary tract infections in people.

16 Jul 2010

Spanish scientists develop new parasite detection method to prevent Anisakidosis

A new method enables anisakids to be detected in any fish product, from a whole fish, fresh or frozen, to tinned fish and surimi. Developed by Spanish scientists, the system is based on molecular techniques and overcomes the limitations of traditional procedures.

16 Jul 2010

Aeras, CHC collaborate in Cambodian tuberculosis prevalence study

The Aeras Global TB Vaccine Foundation and the Cambodian Health Committee today announce the initiation of a study of tuberculosis prevalence in Svay Rieng Province, Cambodia, beginning this month. This is the first study conducted in partnership by the two non-profit research organizations and the first Aeras-sponsored study to be conducted in Cambodia.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

Shrink Nanotechnologies files patent applications for CellAlign advanced tissue engineering technology

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the solar energy production, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign™, have been filed.

15 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

Ligand Pharmaceuticals announces launch of redesigned Web site

Ligand Pharmaceuticals Incorporated announces the launch of its completely redesigned Web site: www.ligand.com. The new Web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about Ligand's business model, robust pipeline, high-profile partnerships and innovative technology.

15 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Biotechnology News and Research

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

GABA disrupts working memory in neurofibromatosis type 1 patients

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

Maxygen's option and licensing arrangement with Cangene expires

ICON opens purpose-built clinical pharmacology unit within CMFT campus

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Amgen granted FDA priority review designation for denosumab BLA

Simulations Plus third-quarter consolidated revenues increase 14.9% to record $3.1 million

Lab-on-Bead technology helps researchers cut years from drug development

Bioethics through the lens of literature

Study analyzes global oncology community's Twitter utilization to enhance discussion at ASCO 2010

Restricted diet can extend lifespan: Study

WPI researchers measure molecular forces that enable cranberry juice to fight off urinary tract infections

Spanish scientists develop new parasite detection method to prevent Anisakidosis

Aeras, CHC collaborate in Cambodian tuberculosis prevalence study

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Shrink Nanotechnologies files patent applications for CellAlign advanced tissue engineering technology

Access announces agreement to develop oral formulation of proprietary injectable drugs

Ligand Pharmaceuticals announces launch of redesigned Web site

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News